Print Page  |  Close Window

2019 News Releases

E-mail Alerts Receive E-mail Alerts | RSS RSS Feeds
Keyword Search
 
2019 | 2018 | 2017 | 2016 | 2015
DateTitle 
07/01/19Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jul. 1, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of Oct. 24, 2006, between LabCorp and The Bank of New York Mellon, as trustee (Trustee) and the conversion agent. In order to ... 
Printer Friendly Version
06/25/19LabCorp to Announce Second Quarter Financial Results on July 25, 2019
BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 25, 2019-- LabCorp® (NYSE: LH) will release its second quarter of 2019 financial results before the market opens on Thursday, July 25, 2019, followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. Interested parties can access the conference call by dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253 internationally, using the passcode 9679477. An audio replay of the conference call will be availabl... 
Printer Friendly Version
06/18/19LabCorp and Mount Sinai Health System Collaborate to Establish Digital and AI-Enabled Pathology Center of Excellence
Philips IntelliSite Pathology Solution will be deployed across the Mount Sinai Health System to support greater efficiency and help improve patient care BURLINGTON, N.C. & NEW YORK & AMSTERDAM--(BUSINESS WIRE)--Jun. 18, 2019-- LabCorp® (NYSE: LH) and the Mount Sinai Health System today announced another element in their shared goal of improving laboratory services and patient care. LabCorp, a leading global life sciences company, and M... 
Printer Friendly Version
06/07/19LabCorp and QIAGEN Announce New therascreen PIK3CA Mutation Analysis Companion Diagnostic for Metastatic Breast Cancer
... 
Printer Friendly Version
06/05/19LabCorp Announces New Leadership Roles
David P. King, current chairman, president and CEO of LabCorp, to become executive chairman of the board of directors effective Nov. 1, retiring Oct. 31 as president and CEO Adam H. Schechter, current lead independent director of LabCorp and longtime Merck executive, to become president and CEO effective Nov. 1 BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 5, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company... 
Printer Friendly Version
06/03/19LabCorp Announces New Term Loan Facility
BURLINGTON, N.C.--(BUSINESS WIRE)--Jun. 3, 2019-- On June 3, 2019, LabCorp® (NYSE: LH) entered into a new Term Loan Credit Agreement, which provides for a two-year term loan credit facility in the principal amount of $850 million (the “New Term Loan Facility”). Bank of America, N.A. is acting as administrative agent for a group of financial institutions providing the New Term Loan Facility. The proceeds from the borrowings under the New Term Loan... 
Printer Friendly Version
06/03/19LabCorp and Envigo Complete Innovative Transactions
LabCorp Acquires Envigo’s Global Nonclinical Contract Research Business, Envigo Acquires LabCorp’s Covance Research Products Business BURLINGTON, N.C. & INDIANAPOLIS--(BUSINESS WIRE)--Jun. 3, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, and Envigo, a leading provider of research models and services, today announced that they have completed previously announced transactions t... 
Printer Friendly Version
05/10/19LabCorp Announces Availability of New QIAGEN therascreen FGFR mutation analysis companion diagnostic for Bladder Cancer
... 
Printer Friendly Version
05/02/19LabCorp to Webcast Its Annual Meeting of Shareholders
BURLINGTON, N.C.--(BUSINESS WIRE)--May 2, 2019-- LabCorp® (NYSE: LH) today announced that its Annual Meeting of Shareholders will be webcast live beginning May 9, 2019, at 9:00 a.m. Eastern Daylight Time via the Company website at www.LabCorp.com. An archived replay of the audio webcast will be available for one year. About LabCorp LabCorp (NYSE: LH), an S&P 500 company, is a leading global life sciences company that is deeply ... 
Printer Friendly Version
04/30/19LabCorp Announces 2019 First Quarter Results and Increases 2019 Earnings Guidance
Q1 revenue of $2.79 billion, down 2% from $2.85 billion last year Q1 diluted EPS of $1.86, up 11% from $1.67 last year; Q1 adjusted EPS of $2.62, down 6% from $2.78 last year 2019 adjusted EPS guidance increased to $11.05 to $11.45, from $11.00 to $11.40 2019 free cash flow guidance of $950 million to $1.05 billion, unchanged from prior guidance BURLINGTON, N.C.--(BUSINESS WIR... 
Printer Friendly Version
04/17/19LabCorp and Envigo Sign Innovative Agreement to Expand Covance’s Nonclinical Drug Development Capabilities and Create an Independent Research Models Provider
LabCorp will purchase Envigo’s nonclinical contract research services business, expanding the global reach and capabilities of Covance’s nonclinical drug development business Envigo’s research models and services business will purchase Covance’s research products business located in the United States, combining two complementary businesses into a new comprehensive research models and services company C... 
Printer Friendly Version
04/01/19LabCorp to Announce First Quarter Financial Results on April 30, 2019
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 1, 2019-- LabCorp® (NYSE: LH) will release its first quarter of 2019 financial results before the market opens on Tuesday, April 30, 2019, followed by a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. Interested parties can access the conference call by dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253 internationally, using the passcode 7459328. An aud... 
Printer Friendly Version
04/01/19Conversion Right Triggered for LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Apr. 1, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of Oct. 24, 2006, between LabCorp and The Bank of New York Mellon, as trustee (T... 
Printer Friendly Version
03/28/19LabCorp Earns 100 Percent on Human Rights Campaign Foundation’s 17th Annual Scorecard on LGBTQ Workplace Equality
Receives Designation as a Best Place to Work for LGBTQ Equality for Second Year in a Row BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 28, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company that is deeply integrated in guiding patient care, today announced that it received a perfect score of 100 on the 2019 Corporate Equality Index (CEI), the nation’s premier benchmarking survey and report on corporate policies and practices related ... 
Printer Friendly Version
03/11/19LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021 to Accrue Contingent Interest
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 11, 2019-- LabCorp® (NYSE: LH) announced today that for the period of March 11, 2019 to Sept. 10, 2019, its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) will accrue (subject to the terms of the Zero Coupon Notes) contingent cash interest at a rate of no less than 0.125% of the average market price of a Zero Coupon Note for the five trading days ended March 6, 2019, in addition to the cont... 
Printer Friendly Version
03/05/19LabCorp is Scheduled to Present at the 2019 Barclays Global Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Mar. 5, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the 2019 Barclays Global Healthcare Conference. LabCorp’s presentation is planned for Tuesday, March 12, 2019, at 8:30 a.m. (ET). A live audio webcast of the presentation will be available via the Company website at www.LabCorp.com and archived for replay. About LabCorp LabCorp (NYSE: LH), an S&P 500 compa... 
Printer Friendly Version
02/19/19LabCorp Strengthens Leadership Position in Precision Medicine with Expansion of Therapeutic Drug Monitoring Portfolio
... 
Printer Friendly Version
02/07/19LabCorp Announces 2018 Fourth Quarter and Full Year Results and Provides 2019 Guidance
Revenue: Q4 of $2.8 billion, up 2% over 2017; Full year of $11.3 billion, up 10% over 2017 Diluted EPS: Q4 of $1.56; Full year of $8.61 Adjusted EPS: Q4 of $2.52, up 11% over 2017; Full year of $11.02, up 20% over 2017 2019 Adjusted EPS guidance of $11.00 to $11.40 2019 Free Cash Flow guidance of $950 million to $1.05 billion Commenced phase II of LabCorp... 
Printer Friendly Version
01/22/19LabCorp Named to FORTUNE Magazine's 2019 List of ‘World’s Most Admired Companies,’ Making the Annual List for the Second Consecutive Year
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 22, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, today announced that it has been named to FORTUNE magazine's 2019 List of World’s Most Admired Companies, making the annual list for the second consecutive year. The annual survey, conducted by FORTUNE and Korn Ferry, a global organizational consulting firm, is given to top executives, directors, and financial analysts to identify the companies... 
Printer Friendly Version
01/16/19LabCorp to Announce Fourth Quarter and Full Year 2018 Financial Results on February 7, 2019
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 16, 2019-- LabCorp® (NYSE: LH) will release its fourth quarter and full year 2018 financial results before the market opens on Thursday, Feb. 7, 2019, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results. The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website. Interested parties can access the ... 
Printer Friendly Version
01/15/19LabCorp and Texas Association of Community Health Centers Extend Agreement for LabCorp to Be Exclusive Laboratory for Community Health Centers Across Texas
LabCorp Will Provide Enhanced Laboratory Services, With an Emphasis on Chronic Diseases, for Clinics Serving More Than One Million Patients Annually BURLINGTON, N.C. & AUSTIN, Texas--(BUSINESS WIRE)--Jan. 15, 2019-- LabCorp® (NYSE: LH) a leading global life sciences company, and the Texas Association of Community Health Centers, Inc. (TACHC) a private, non-profit association of approximately 75 community health centers with more than 500 s... 
Printer Friendly Version
01/03/19Conversion Right Triggered For LabCorp’s Zero Coupon Convertible Subordinated Notes Due 2021
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 3, 2019-- LabCorp® (NYSE: LH) announced today that its Zero Coupon Convertible Subordinated Notes due 2021 (Zero Coupon Notes) may be converted as set forth below. The Zero Coupon Notes are convertible into cash and Common Stock of LabCorp, if any, subject to the terms of the Zero Coupon Notes and the Indenture, dated as of October 24, 2006 between LabCorp and The Bank of New York Mellon, as trustee ... 
Printer Friendly Version
01/03/19GENFIT and LabCorp Sign a Licensing Agreement to Expand Access to an Innovative Diagnostic Assay for Non-Alcoholic Steatohepatitis (NASH)
Multi-Biomarker Test Will Provide the Clinical Research Community with a Non-Invasive Tool to Identify and Monitor Patients with NASH and Significant Fibrosis LILLE, France & CAMBRIDGE, Mass. & BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 3, 2019-- LabCorp® (NYSE: LH), a leading global life sciences company, and GENFIT (Euronext: GNFT), a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targe... 
Printer Friendly Version
01/02/19LabCorp is Scheduled to Present at the 37th Annual J.P. Morgan Healthcare Conference
BURLINGTON, N.C.--(BUSINESS WIRE)--Jan. 2, 2019-- LabCorp® (NYSE: LH) today announced it will participate at the 37th Annual J.P. Morgan Healthcare Conference. LabCorp’s presentation is scheduled for Tuesday, January 8, 2019 at 1:30 p.m. (PT), followed by a question and answer session at 2:00 p.m. (PT). A live audio webcast of the presentation and the subsequent question and answer session will be available via the Company website at www.labcorp.... 
Printer Friendly Version